Obupro (4 mg/ml Eye Drops, Solution)
Ophthalmic solution containing obupro — prescription medication for topical ocular use
Quick Facts About Obupro
Key Takeaways About Obupro
- Prescription only: Obupro is a prescription ophthalmic medication and must be used under the supervision of an eye-care professional
- For the eye only: Obupro 4 mg/ml is intended exclusively for topical instillation into the eye — never inject, swallow, or apply to other body sites
- Correct technique matters: Proper instillation technique, including nasolacrimal occlusion, improves efficacy and reduces systemic absorption
- Avoid contamination: Do not let the dropper tip touch the eye, eyelid, fingers, or any surface; this is the leading cause of ocular infection from eye drops
- Contact lenses: Remove contact lenses before instilling Obupro and wait at least 15 minutes before reinserting them
What Is Obupro and What Is It Used For?
Obupro is a prescription ophthalmic medication supplied as a sterile 4 mg/ml eye drops solution containing the active substance obupro. It is instilled directly into the affected eye(s) and prescribed by an ophthalmologist or other qualified physician based on the patient's individual ocular condition and clinical assessment.
Obupro belongs to the broad therapeutic category of topical ophthalmic medicines, a group of pharmaceutical products formulated specifically for direct application to the eye. Topical ophthalmic preparations such as eye drops, gels, and ointments allow medication to act locally on ocular tissues at high concentrations while limiting systemic exposure compared with oral or injected formulations. As a prescription-only medicine, Obupro has been evaluated by regulatory authorities including the European Medicines Agency (EMA) and is supplied in accordance with national pharmacovigilance and quality standards.
The active substance in Obupro is obupro, present at a concentration of 4 mg per millilitre of solution. This concentration has been formulated to deliver a clinically appropriate dose to the ocular surface and underlying tissues with each drop administered. A single drop dispensed from a typical ophthalmic dropper bottle has a volume of approximately 30 to 50 microlitres, meaning that the absolute amount of active substance delivered per drop is calibrated to balance therapeutic efficacy with minimisation of side effects.
Like all prescription ophthalmic medications, Obupro is intended only for the patient and indication for which it has been prescribed. Eye conditions can appear superficially similar but have entirely different underlying causes — for example, a "red eye" can be caused by infection, allergy, inflammation, raised intraocular pressure, or trauma, and each requires a different treatment approach. Self-medicating with another person's eye drops, or with a previously prescribed bottle for a new symptom, can mask serious disease and delay appropriate care.
Your prescribing physician will explain the specific indication for which Obupro has been chosen for you, the expected duration of therapy, and what clinical improvement to anticipate. The eye is a particularly sensitive organ, and even minor changes in symptoms — such as worsening redness, pain, blurred vision, or photophobia — should prompt immediate medical re-evaluation rather than alteration of self-administered treatment.
Obupro is a prescription-only ophthalmic medication. Do not share this medicine with others, even if their eye symptoms appear similar to yours. Many eye conditions look alike but have different causes that require different treatments. Always use Obupro exactly as directed by your prescribing physician, and contact your eye-care professional promptly if symptoms persist or worsen.
What Should You Know Before Using Obupro?
Before starting Obupro eye drops, inform your doctor about any allergies, ocular conditions, recent eye surgery, contact lens use, pregnancy or breastfeeding status, and all current medications including other eye drops. Your physician will assess whether Obupro is appropriate for you and may need to adjust other ocular treatments accordingly.
Contraindications
Do not use Obupro if you are allergic (hypersensitive) to obupro itself or to any of the excipients in the eye drops formulation. Hypersensitivity reactions in the eye may include marked conjunctival redness, eyelid swelling (blepharoedema), severe itching, watery discharge, or skin reactions on the eyelids. Systemic allergic features such as facial swelling, throat tightness, or difficulty breathing are rare with topical eye drops but require immediate emergency care if they occur.
Many ophthalmic solutions contain the preservative benzalkonium chloride or related quaternary ammonium compounds. These preservatives prevent microbial growth in the bottle but can themselves cause allergic or toxic reactions to the ocular surface, especially with prolonged use. If you have known intolerance to ophthalmic preservatives, inform your doctor; preservative-free formulations may be available in some cases. The complete list of excipients is provided in the patient information leaflet supplied with each pack of Obupro.
Use of Obupro should be avoided if you have an active untreated ocular infection that has not been evaluated by an eye-care professional, an undiagnosed eye injury, or any condition for which the underlying cause has not been determined. Applying any eye drop, including Obupro, to an undiagnosed red or painful eye risks masking signs of serious pathology such as bacterial keratitis, herpetic eye disease, or angle-closure glaucoma.
Warnings and Precautions
Talk to your doctor or pharmacist before using Obupro if any of the following apply to you:
- Recent eye surgery or eye injury: The healing ocular surface may be more vulnerable to medication effects and to contamination from the dropper tip
- Existing eye disease: Conditions such as dry eye disease, blepharitis, glaucoma, uveitis, or corneal disease can influence drug response and require monitoring
- Use of multiple eye drops: If more than one ophthalmic medication is prescribed, instil them at least 5–10 minutes apart to prevent the second drop from washing away the first
- Contact lens wear: Lenses should be removed before each dose; many preservatives accumulate in soft lens materials and may cause discoloration or irritation
- Children and infants: The safety and efficacy of Obupro in paediatric patients should be assessed individually by a paediatric ophthalmologist
- Driving and operating machinery: Eye drops can cause transient blurred vision after instillation; do not drive or operate machinery until your vision has cleared
Regular follow-up with your prescribing eye-care professional is essential during treatment with Obupro. Depending on the indication, your physician may schedule slit-lamp examinations, intraocular pressure measurements, visual acuity testing, or other clinical assessments to verify treatment response and detect any adverse effects on the ocular surface or deeper structures of the eye. Attend all scheduled appointments and report any new or worsening symptoms promptly between visits.
Patients who experience reduced tear production (dry eye), corneal disease, or who use multiple preserved eye drops are at higher risk of preservative-related ocular surface toxicity. Symptoms can include burning, foreign-body sensation, redness, and a sensation of dryness that paradoxically worsens with continued drop use. If these symptoms develop, inform your doctor; a change in formulation, addition of preservative-free lubricants, or temporary treatment break may be considered.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Obupro. Although topical ophthalmic medications generally result in lower systemic exposure than oral or injected drugs, a small amount of any eye drop is absorbed through the conjunctival blood vessels and through the nasolacrimal duct into the nose and throat. The safety of Obupro during pregnancy has not been definitively established, and your doctor will weigh the potential benefits against the theoretical risks.
Pregnant women can reduce systemic absorption of any eye drop substantially by performing nasolacrimal occlusion: gently pressing the inner corner of the eye (over the tear duct) for one to two minutes after instillation. This simple technique is recommended for any ophthalmic medication used during pregnancy and breastfeeding.
It is not known whether obupro passes into breast milk after ophthalmic administration. If you are breastfeeding or planning to breastfeed, discuss this with your doctor before starting Obupro. Your healthcare provider will consider the importance of treatment for your eye condition and the theoretical exposure to your nursing infant. As with pregnancy, nasolacrimal occlusion can reduce systemic absorption and any subsequent passage into breast milk.
Women of childbearing potential should inform their prescriber if they become pregnant during treatment so that the risks and benefits can be reassessed. Do not stop, start, or change Obupro therapy without medical advice.
Do not start, stop, or change the dose of Obupro without consulting your healthcare provider. If you are pregnant or breastfeeding, your physician will assess the individual risk-benefit balance and may recommend nasolacrimal occlusion to minimise systemic absorption.
How Does Obupro Interact with Other Drugs?
Obupro may interact with other ophthalmic and systemic medications. Always inform your doctor and pharmacist about all medicines you are using — including other eye drops, oral prescription drugs, over-the-counter products, vitamins, and herbal supplements — so that the risk of interactions can be minimised.
Drug interactions with topical ophthalmic medications fall into two main categories. First, local interactions occur when two or more eye drops are used in the same eye and one alters the absorption, retention, or pharmacological effect of the other. Second, systemic interactions occur when the small amount of drug absorbed through the conjunctiva or the nasolacrimal duct reaches the bloodstream and interacts with oral or parenteral medications. Although systemic absorption of eye drops is modest, it is not negligible, and clinically meaningful interactions can occur with potent agents.
The most common local interaction is dilution: when two ophthalmic preparations are instilled within a few minutes of each other, the second drop washes away part of the first before it has been absorbed. This can substantially reduce the effective dose of either medication. International ophthalmic guidelines therefore recommend separating the instillation of different eye drops by at least 5 to 10 minutes, with longer intervals (10–15 minutes) recommended for ophthalmic gels, ointments, and viscous solutions.
Pharmacokinetic and pharmacodynamic interactions can also occur when Obupro is used together with systemic medications. For example, certain oral drugs may alter the metabolism of ophthalmic medications, while others may have additive or opposing pharmacological effects on ocular tissues, intraocular pressure, or pupillary size. Your prescriber will review your full medication list to identify any potentially significant interactions before initiating therapy.
Patients should always carry an up-to-date list of all medications, including ophthalmic products, oral prescription drugs, over-the-counter remedies, vitamins, herbal preparations, and any recently discontinued medications. Present this list at every healthcare visit, including dental appointments and emergency department attendances.
Potential Drug Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Other ophthalmic eye drops | Local (dilution / washout) | May reduce effective dose of either drop | Separate instillations by 5–10 minutes |
| Ophthalmic gels and ointments | Local (barrier / retention) | Viscous formulations may impair absorption of solutions | Apply gels/ointments last; allow 10–15 minutes |
| Anticoagulants (e.g., warfarin, DOACs) | Pharmacodynamic | Theoretical increased bleeding risk if conjunctival or surgical bleeding | Inform prescriber of anticoagulant therapy |
| Other topical preserved eye drops | Cumulative ocular surface toxicity | Increased risk of dry eye, irritation, and corneal damage | Consider preservative-free alternatives where available |
| Soft contact lenses (with preserved formulations) | Material absorption | Preservatives may accumulate in lens material and cause irritation | Remove lenses before each dose; reinsert after at least 15 minutes |
| Herbal supplements (e.g., St John's Wort) | Pharmacokinetic (systemic) | May alter metabolism of small absorbed fraction | Disclose all supplement use to prescriber |
The table above is not exhaustive. Many other ophthalmic and systemic medications may potentially interact with Obupro. The clinical relevance of any interaction depends on multiple factors, including the doses involved, the duration of concurrent therapy, the patient's overall health, and the presence of other ocular or systemic conditions. Always discuss new prescriptions, dietary supplements, and over-the-counter remedies with your eye-care provider or pharmacist before starting them alongside Obupro.
Minor Interactions and Practical Considerations
Some interactions are minor or theoretical and rarely cause clinical problems, but awareness of them can help patients optimise their treatment. Examples include the timing of artificial tears (lubricant eye drops), which should ideally be used at least 5–10 minutes after Obupro to avoid dilution, and the use of cosmetic products around the eye, which should be applied after the medication has been absorbed and the eye is no longer wet.
Alcohol does not have a known direct interaction with topical ophthalmic obupro. However, alcohol can worsen dry eye symptoms and may interact with other systemic medications you are taking. Discuss alcohol use with your doctor in the context of your overall treatment plan.
What Is the Correct Dosage of Obupro?
The standard formulation of Obupro is a 4 mg/ml ophthalmic solution. The number of drops per dose, the frequency of dosing, and the duration of therapy will be specified by your prescribing physician based on your individual diagnosis and clinical response. Always follow your doctor's instructions exactly and never alter the dose without medical advice.
Dosing of ophthalmic medications differs fundamentally from oral medications. Each drop dispensed from a standard ophthalmic dropper contains approximately 30 to 50 microlitres of solution, while the conjunctival sac of the human eye can hold only about 7 to 10 microlitres before excess fluid spills onto the cheek or drains into the nose via the nasolacrimal duct. This means that a single correctly instilled drop is normally sufficient to deliver a therapeutic dose; instilling two drops in rapid succession does not double the dose but mostly results in waste and increased systemic absorption.
How to Instil Obupro Correctly
Correct instillation technique improves both the efficacy and safety of Obupro. Follow these evidence-based steps for each dose:
- Wash your hands thoroughly with soap and water before handling the bottle
- Check the bottle for clarity and the expiry date; do not use if the solution is discoloured or the bottle is damaged
- Tilt your head back or lie down, and look up at the ceiling
- Pull the lower eyelid down gently with a clean finger to create a small pocket between the eyelid and the eyeball
- Hold the bottle above the eye, dropper tip down, without letting it touch your eye, eyelid, eyelashes, fingers, or any other surface
- Squeeze one drop into the pocket formed by the lower eyelid
- Close your eye gently for one to two minutes — do not blink forcefully or squeeze the eyelids tightly
- Apply gentle pressure to the inner corner of your eye (over the tear duct) for one to two minutes; this nasolacrimal occlusion reduces drainage into the nose and minimises systemic absorption
- Wipe away any excess solution from around the eye with a clean tissue
- Replace the cap immediately and store the bottle as directed
If you have been prescribed eye drops for both eyes, repeat the process for the other eye. If you have been prescribed more than one type of eye drop, wait at least 5 to 10 minutes between different products to prevent dilution. If one of your medications is an ophthalmic gel or ointment, use it last, as it forms a film over the eye that can impair absorption of subsequent solutions.
Adults
Standard Adult Dosage
The typical adult dose of Obupro 4 mg/ml is one drop instilled into the affected eye(s), with the frequency determined by your prescribing physician based on the indication. Common dosing intervals for ophthalmic medications range from once daily to several times per day. Your doctor will explain the specific schedule appropriate for your condition. Maintain consistent timing of doses to optimise therapeutic effect.
Do not increase the number of drops or the frequency of dosing without medical advice. Excess drops do not improve efficacy and may increase the risk of side effects, including ocular surface toxicity from repeated preservative exposure and systemic absorption through the nasolacrimal system.
Children and Adolescents
Paediatric Use
The safety and efficacy of Obupro in children and adolescents under 18 years of age have not been comprehensively established for all indications. Where Obupro is prescribed for paediatric patients, this should be done by, or in consultation with, a paediatric ophthalmologist or other specialist with expertise in children's eye health. Children may have different drug responses, smaller conjunctival sacs (further reducing the volume that can be retained per drop), and a higher surface-area-to-body-weight ratio that can increase systemic exposure proportionally.
Caregivers should learn correct instillation technique from the prescriber or pharmacist, including how to position a young child safely and how to soothe a child who is anxious about eye drops. If a child resists treatment, do not force the bottle into the eye area, as this risks corneal abrasion or contamination of the dropper tip.
Elderly Patients
Geriatric Dosage Considerations
Older adults often have age-related changes in the ocular surface, including reduced tear production, slower blink reflex, and a higher prevalence of dry eye disease. These factors can prolong the residence time of eye drops on the ocular surface and may increase the likelihood of preservative-related side effects. Manual dexterity, hand tremor, and visual impairment can also make accurate instillation more difficult.
Elderly patients should be assessed for their ability to self-administer eye drops correctly. Where necessary, family members, caregivers, or assistive devices (such as eye-drop guides or bottle aids) can improve technique and adherence. Regular follow-up with the prescribing physician is particularly important in this age group to monitor for ocular surface changes.
Missed Dose
If you forget to instil a dose of Obupro, do so as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not instil a double dose to compensate for a forgotten one — as explained above, the eye cannot retain more than a single drop, and excess solution simply drains away or is absorbed systemically.
Consistent dosing intervals help maintain steady drug concentration in the ocular tissues. If you frequently forget doses, consider linking instillation to daily routines (such as brushing teeth in the morning and at bedtime), using a phone alarm, or asking a family member to remind you. If multiple doses have been missed, contact your prescribing physician for guidance on resuming therapy.
Overdose
Topical overdose of an eye drop is unusual because the eye cannot retain more than a single drop at a time; excess solution simply spills onto the cheek. However, if Obupro is accidentally swallowed (for example, by a child who finds a bottle), or if a large quantity is administered into the eye, contact your local poison control centre or attend the nearest emergency department immediately. Bring the bottle and packaging so that medical staff can verify the product, concentration, and amount potentially ingested. Symptoms of systemic exposure depend on the active substance and the dose involved.
| Patient Group | Standard Approach | Notes |
|---|---|---|
| Adults | One drop in affected eye(s) as prescribed | Frequency and duration determined by prescribing physician |
| Elderly (≥65 years) | Standard adult dose, with technique review | Assess instillation ability; monitor for ocular surface side effects |
| Children (<18 years) | Use only under specialist supervision | Caregiver should be trained in correct instillation technique |
| Pregnancy | Use only if benefit outweighs theoretical risk | Use nasolacrimal occlusion to reduce systemic absorption |
| Renal or hepatic impairment | Standard topical dose generally appropriate | Systemic exposure from eye drops is normally low; consult prescriber |
What Are the Side Effects of Obupro?
Like all medicines, Obupro eye drops can cause side effects, although not everyone experiences them. Most reactions are mild and limited to the ocular surface. Contact your doctor immediately if you experience severe pain, sudden vision loss, persistent redness, or signs of an allergic reaction.
Side effects of ophthalmic medications are conventionally classified by frequency, following the European Medicines Agency's standard categories: very common (affecting more than 1 in 10 users), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and very rare (fewer than 1 in 10,000). Reactions to topical eye drops are predominantly local, affecting the conjunctiva, cornea, eyelids, and surrounding skin, but systemic reactions are possible if a sufficient quantity is absorbed through the nasolacrimal route.
It is important to distinguish between expected pharmacological effects, ocular surface irritation, preservative-related reactions, and true allergic responses. Brief stinging or burning lasting a few seconds after instillation is common with many eye drops and usually resolves quickly. Persistent burning, increasing redness, swelling of the eyelids, or itching that worsens over days may indicate a hypersensitivity or toxic reaction and should be reported to your prescribing physician.
Many side effects improve as the ocular surface adapts to the medication during the first one to two weeks of treatment. However, patients should be alert to warning signs that warrant urgent attention: severe ocular pain, sudden decrease in vision, photophobia (sensitivity to light), perception of haloes around lights, marked eyelid swelling, or any signs of systemic allergic reaction such as facial swelling, throat tightness, or breathing difficulties. These symptoms require prompt medical assessment.
Common Side Effects
May affect up to 1 in 10 people
- Transient stinging or burning on instillation
- Mild redness of the conjunctiva
- Brief blurred vision immediately after instillation
- Foreign-body sensation or grittiness
- Increased tear production (reflex lacrimation)
- Itching of the eye or eyelids
Uncommon Side Effects
May affect up to 1 in 100 people
- Persistent dryness of the ocular surface
- Eyelid swelling or oedema
- Conjunctival follicles or papillae
- Punctate keratitis (small areas of corneal staining)
- Sensitivity to light (photophobia)
- Headache
- Unusual taste in the mouth (from drainage via the tear duct)
Rare Side Effects
May affect up to 1 in 1,000 people
- Allergic conjunctivitis or contact dermatitis of the eyelids
- Corneal ulceration or epithelial defect
- Persistent visual disturbance
- Generalised hypersensitivity reaction
- Systemic effects from absorbed medication (uncommon at therapeutic ophthalmic doses)
Sudden loss or marked reduction in vision; severe eye pain; signs of a serious allergic reaction such as swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; widespread skin rash; or marked unilateral eye pain with vomiting (which can suggest acute angle-closure glaucoma). Stop using Obupro and call your local emergency number or attend the nearest emergency department immediately.
You are encouraged to report any suspected side effects to your healthcare provider or to your national pharmacovigilance authority. In the European Union, side effects can be reported via the national reporting systems listed at www.ema.europa.eu; in the United States, via the FDA MedWatch programme at www.fda.gov; and in the United Kingdom, via the MHRA Yellow Card Scheme. Reporting helps regulatory authorities identify previously unrecognised adverse reactions and improve the safety information available to all patients.
How Should You Store Obupro?
Store Obupro at room temperature below 25 °C (77 °F) in the original carton to protect from light. After first opening, the bottle should typically be discarded after 4 weeks (or as stated on the label) to minimise the risk of microbial contamination. Keep out of reach and sight of children, and do not use after the expiry date.
Proper storage of ophthalmic medications is essential to maintain their sterility, chemical stability, and clinical effectiveness. Eye drops are formulated as sterile solutions, and any breach of sterility — whether through contamination of the dropper tip, prolonged use after opening, or improper storage conditions — can introduce micro-organisms that may cause serious eye infection, including bacterial keratitis or endophthalmitis. The eye is a relatively immunoprivileged site, and infections that begin from contaminated eye drops can progress rapidly.
Store Obupro in a cool, dry place at a temperature not exceeding 25 °C (77 °F). Avoid exposing the bottle to direct sunlight, heat sources such as radiators or car interiors in summer, or the high humidity of bathrooms. Store the bottle in the original carton; the carton protects the active substance from light, which can degrade certain ophthalmic agents over time. If your patient information leaflet specifies refrigeration before first opening, follow those instructions precisely.
Once a bottle of Obupro has been opened for the first time, the in-use shelf life is shorter than the printed expiry date because the integrity of the preservative system declines after exposure to air and the dropper tip. The standard recommendation for most preserved multi-dose ophthalmic solutions is to discard the bottle 4 weeks after first opening, but always check the patient information leaflet supplied with your specific product. Many patients find it helpful to write the date of opening on the carton with a permanent marker.
Always keep Obupro and all medications out of the reach and sight of children. Eye drops are particularly hazardous if swallowed by a small child, because the volume in a single bottle may contain a substantial systemic dose. Store medications in a locked cabinet or in a location that children cannot access. Accidental ingestion of any prescription medication by a child is a medical emergency and warrants immediate contact with poison control or emergency services.
Do not use Obupro after the expiry date stated on the bottle and carton. The expiry date refers to the last day of that month. Expired ophthalmic solutions may have reduced effectiveness, altered chemical composition, or compromised sterility, and could potentially cause harm if used.
Do not dispose of Obupro via wastewater or household waste. Return any unused or expired bottles to your pharmacy for safe disposal. Many pharmacies and healthcare facilities offer medication take-back programmes that ensure pharmaceutical waste is processed appropriately. Proper disposal helps protect water supplies and prevents accidental exposure of others.
What Does Obupro Contain?
Each millilitre of Obupro ophthalmic solution contains 4 mg of the active substance obupro, together with sterile pharmaceutical excipients that maintain pH, tonicity, sterility, and stability of the formulation.
The active ingredient in Obupro is obupro, present at a concentration of 4 mg per millilitre of solution. This is the substance responsible for the therapeutic effect on the eye. The concentration has been determined through pharmaceutical development to deliver an appropriate ocular dose with each drop while remaining well tolerated by the conjunctiva and cornea.
In addition to the active substance, Obupro eye drops contain inactive ingredients (excipients) that perform essential pharmaceutical functions. Typical excipients in ophthalmic solutions include: a preservative system (such as benzalkonium chloride or alternative preservatives) to maintain sterility of multi-dose bottles; tonicity-adjusting agents (such as sodium chloride) to match the osmolality of natural tears; pH buffers (such as citrate or phosphate buffers) to keep the solution within a comfortable physiological range; viscosity-enhancing polymers in some formulations to prolong contact time on the ocular surface; and water for injection as the solvent. The complete list of excipients for your specific batch of Obupro is provided in the patient information leaflet supplied with each pack.
If you have known allergies or intolerances to specific pharmaceutical excipients — for example, sensitivity to benzalkonium chloride, sulphites, or particular phosphate buffer systems — discuss this with your doctor or pharmacist before starting Obupro. Where intolerance to a standard excipient is suspected, alternative formulations (such as preservative-free single-dose units) may be available for some ophthalmic indications.
Patients should be aware that the appearance of Obupro should remain consistent throughout its shelf life. The solution should normally be clear and free of particulate matter. If you notice changes in colour, cloudiness, particles floating in the solution, or any unusual odour, do not use the bottle and return it to your pharmacist. These changes may indicate degradation or contamination of the formulation.
The container and dropper system are also part of the medicinal product. Obupro is supplied in a multi-dose bottle with an integrated dropper that delivers a calibrated drop volume. Do not transfer the solution to another container, as this can compromise sterility and may alter the dose delivered with each drop. Use only the original packaging for the entire course of treatment.
Frequently Asked Questions About Obupro
Obupro is a prescription ophthalmic medication supplied as a 4 mg/ml eye drops solution containing the active substance obupro. It is administered topically to the eye and prescribed by an ophthalmologist or other qualified physician based on the individual patient's eye condition. Because eye disorders that look similar can have very different underlying causes, only a qualified prescriber can determine whether Obupro is the correct treatment for your symptoms.
Wash your hands. Tilt your head back, gently pull down the lower eyelid to form a small pocket, and squeeze one drop into the pocket without letting the bottle tip touch your eye, eyelid, or any other surface. Close the eye gently for one to two minutes and apply light pressure to the inner corner of the eye (over the tear duct) to reduce systemic absorption via the nasolacrimal route. Wipe away any excess and replace the cap immediately. If using more than one type of eye drop, wait at least 5–10 minutes between products.
If you miss a dose of Obupro, instil it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Never instil two drops to compensate for a missed dose — the eye cannot hold more than one drop at a time, and the excess simply drains away or increases systemic absorption. Use phone alarms, pill organisers, or routine cues such as brushing your teeth to help you remember your eye drops consistently.
It is generally recommended to remove contact lenses before instilling Obupro and to wait at least 15 minutes before reinserting them. Many ophthalmic solutions contain preservatives such as benzalkonium chloride that can be absorbed by soft contact lens materials, potentially causing discoloration, lens damage, or ocular irritation. During acute eye disease, your ophthalmologist may recommend avoiding contact lenses entirely until treatment is complete and the eye has fully recovered.
No, Obupro is classified as a prescription-only ophthalmic medication (Rx). A valid prescription from a licensed healthcare provider, such as an ophthalmologist or general practitioner, is required to obtain it from a pharmacy. The prescription requirement ensures that the medication is used under appropriate medical supervision, with proper diagnosis of your eye condition and monitoring for response and side effects. Do not attempt to obtain or use Obupro without a prescription, and never use another person's eye drops.
Store Obupro at room temperature below 25 °C (77 °F) in the original carton to protect from light. Keep the bottle tightly closed when not in use, and avoid storing eye drops in humid environments such as bathrooms. After first opening, the bottle should typically be discarded after 4 weeks (or as stated on the patient information leaflet) to minimise the risk of microbial contamination. Keep out of reach and sight of children. Do not use after the expiry date printed on the carton, and return any unused product to your pharmacy for safe disposal.
An unusual or bitter taste in the mouth shortly after instilling eye drops is a recognised effect of many ophthalmic medications. It occurs because tear fluid drains from the eye through the nasolacrimal duct into the back of the nose and throat, where some of the medication is tasted. This effect can be reduced by performing nasolacrimal occlusion — gently pressing the inner corner of the eye for one to two minutes after instillation — which also reduces systemic absorption. The taste is usually harmless but should be mentioned to your prescriber if it is bothersome or persistent.
References and Sources
This article is based on internationally recognised medical, pharmaceutical, and ophthalmic guidelines. All information has been reviewed by qualified healthcare professionals and follows evidence-based principles consistent with the GRADE framework and Level 1A evidence sources where available.
- European Medicines Agency (EMA). Guideline on Summary of Product Characteristics (SmPC) for Ophthalmic Medicinal Products. EMA, 2024. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization, 2023.
- British National Formulary (BNF). Prescribing in Ophthalmology: Instillation Technique, Drug Interactions, and Adverse Effects. NICE, 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Ophthalmic Drug Products: Drug Safety Communications and Labelling Guidance. FDA, 2024. Available at: www.fda.gov
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics — Ocular Pharmacology Chapter. 14th Edition. McGraw-Hill Education, 2023.
- European Pharmacopoeia Commission. European Pharmacopoeia, 11th Edition — Ophthalmic Preparations Monograph. Council of Europe, 2023.
- Royal College of Ophthalmologists. Guidelines on the Use of Topical Ophthalmic Medications. RCOphth, 2023. Available at: www.rcophth.ac.uk
- International Council for Harmonisation (ICH). ICH E2C(R2): Periodic Benefit-Risk Evaluation Report. ICH, 2023.
- American Academy of Ophthalmology. Preferred Practice Pattern Guidelines — Topical Therapy and Patient Education. AAO, 2023.
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, consisting of licensed physicians and specialists in ophthalmology and clinical pharmacology with expertise in ophthalmic drug therapy, drug safety, pharmacovigilance, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in ophthalmology and clinical pharmacology. All content is researched and written using peer-reviewed sources and international ophthalmic and pharmaceutical guidelines.
iMedic Medical Review Board – an independent panel of qualified physicians who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, WHO, and Royal College of Ophthalmologists standards.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.